Evaluate the cost-effectiveness of female-only vs. gender-neutral HPV vaccination in Japan.
Comparison of 4vHPV and 9vHPV strategies
Analysis based on Japan's economic standards
Assessment of health benefits
Both female-only 4vHPV and 9vHPV strategies are cost-effective
Gender-neutral vaccination with 9vHPV offers greater health benefits and cost-effectiveness
Abstract
Both female-only 4vHPV and 9vHPV strategies are cost-effective under Japan's economic standards. Furthermore, GNV with 9vHPV provides greater health benefits and cost-effectiveness.